| Date Filed | Type | Description |
| 10/13/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 07/24/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/20/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 07/12/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/05/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/21/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State... |
| 02/14/2023 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 1.4% stake in Catalyst Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 0% stake in Catalyst Biosciences, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/05/2023 |
3
| Eastling Thomas Wilson (Director) has filed a Form 3 on CATALYST BIOSCIENCES, INC. |
| 01/05/2023 |
3
| GNI Group Ltd. (10% Owner) has filed a Form 3 on CATALYST BIOSCIENCES, INC. |
| 01/05/2023 |
3
| Luo Ying (Director) has filed a Form 3 on CATALYST BIOSCIENCES, INC. |
| 12/27/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/27/2022 |
8-K
| Investor presentation|
Docs:
|
"by and among CATALYST BIOSCIENCES, INC., as the Buyer, and GNI GROUP LTD., and GNI HONG KONG LIMITED, as the Sellers Dated as of December 26, 2022",
"BUSINESS COMBINATION AGREEMENT",
"Certificate of Designation of Series X Convertible Preferred Stock",
"Amended and Restated Bylaws of Catalyst Biosciences, Inc",
"“Agreement”) is made and entered into as of [date] between Catalyst Biosciences, Inc., a Delaware corporation , and [name of director], a director, officer or member of the executive committee of the Company (“Indemnitee”",
"Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction",
"Presentation for investor conference call held by Catalyst Biosciences, Inc. on December 27, 2022" |
|
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/04/2022 |
8-K
| Quarterly results |
| 10/07/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/22/2022 |
SC 13D/A
| JEC II Associates, LLC reports a 0% stake in Catalyst Biosciences, Inc. |
| 08/25/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/19/2022 |
SC 13D/A
| SINGER JULIAN D. reports a 7.1% stake in Catalyst Biosciences, Inc. |
| 08/19/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
|